ASH Stock Analysis — Ashland Inc.
Sector: Specialty Chemicals
AI Verdict
ASH trades at a discount to the sector on forward earnings, but with shrinking sales, you're betting that its moat can offset a lack of growth.
Competitive Moat
Ashland specializes in high-performance specialty additives and ingredients for industries like personal care, pharmaceuticals, and coatings, where regulatory hurdles and customer formulation lock-in create switching costs. Its defensibility comes from proprietary chemistries and long-term customer integration in regulated end markets.
Summary
Ashland trades at 17.3x next year's earnings despite a recent -1.4% drop in revenue, putting the spotlight on margin resilience over growth.
Where It Stands
With a forward P/E of 17.3x versus the chemicals sector median of ~20x and negative -1.4% revenue growth, the stock is priced below peers but faces top-line headwinds.
Key Metrics
- Forward P/E: 17.3x
- Revenue Growth: -0.0%
- Dividend Yield: 0.02%
- 52-Week High: $78.25
- 52-Week Low: $46.30
Analyst Consensus
12 Buy · 4 Hold · 0 Sell (16 analysts)
Bull Case
At 17.3x forward earnings, investors are paying less than the sector average for a business with entrenched customer relationships and regulatory barriers.
Bear Case
If the revenue decline persists, a further P/E compression from 17.3x to the low teens could mean a double-digit downside for the stock.
Catalyst to Watch
Watch for the next earnings report to see if revenue stabilizes or rebounds, as another negative print could trigger further derating.